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Institut Jules Bordet, Brussels, Belgium
The loco-regional control of NSCLC
remains a major challenge but it is a
requirement for cure: classical radiation
schedule delivering dose in the range of
60 to 65 Gy yield a very poor local control
(less than 20%). Recent trials have clearly
demonstrate that it was possible to
improve the local control and this translate
in a clear survival benefit. This was
observed with accelerated hyperfra-
ctionated radiation (CHART and HART)
but also with concurrent chemo-radiothe-
rapy approach (Furuse, Schaake-Koning
trials). The recent major technological
development both in treatment planning
and radiation delivery has opened the road
to look for an escalation in the total
radiation dose far above the past threshold
dose of 65 Gy. What have we learned from
the current experience? It is possible to go
above this limit of 65 Gy but doses
escalation is often limited by the tolerance
of normal tissues especially the amount of
irradiated normal lung. To overcome this
restriction, the current philosophy is to
treat only the gross tumor volume and to
avoid any elective nodal irradiation. This
implies to have a good mediastinal eva-
luation (PET is particularly useful). Indeed,
nodal failures are reported to be a rare
event while controlling the primary tumor
remains the challenge. Doses as high as
90 Gy can be delivered but there is a
paradoxal issue: this is often only possible
for small tumors probably not requiring this
high dose while larger tumors can not be
treated to this level. The second problem
is the issue of repopulation: increasing
treatment duration by only using daily 2 Gy
per fraction will certainly not be as
effective as expected: the only solution is
either using an hyperfractionating sche-
dule or higher daily dose (concomitant
boost technique). Additional studies are
clearly needed to see the real impact of
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this approach on a large population scale
and not only to very select patients able to
follow the guidelines for very complicate
set-up (the different gating techniques).
Furthermore, longer follow-up will be
needed to assess the possible late effects
at the level of the lung and the heart. Last
but not least, this technique should be in a
next step be part of a multimodal
approach.
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COMBINED CHEMOTHERAPY AND
RADIATION IN LOCALLY
ADVANCED INOPERABLE NSCLC
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Lung cancer is the leading cause of
cancer death around the world. Non-small
cell lung cancer (NSCLC) accounts for
three quarters of all lung tumors. Surgery
is the cornerstone of treatment in localized
NSCLC but only 20% of patients are con-
sidered surgical candidates at presen-
tation. The vast majority of patients cannot
be subjected to surgery either because of
tumor advancement or poor medical
condition. Radiation therapy has tradi-
tionally been considered the mainstay of
treatment in inoperable stage III disease.
Irradiation, however, is in principle used for
palliation since in most instances this
method does not allow for eradication of
bulky disease in the thorax. Moreover,
radiotherapy does not prevent uncontrolled
systemic disease, which is the major
cause of death in locally advanced
NSCLC. In consequence, the prognosis of
patients with locally advanced tumours is
dismal and has remained essentially
unchanged within the last decades. The
five-year survival rates after irradiation
vary between 3 and 6%. One of the
attempts to improve the outcome is
combining radiation with chemotherapy.
This strategy seems to be particularly
interesting as it may potentially increase
the cure rate not only by improved
locoregional tumour control but also by
elimination of micrometastases outside the
radiotherapy field. Chemotherapy and
radiation may be applied in sequence or
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